6515--diagnostic radiotracer for beta amyloid protein used for Alzheimer's patients.

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 is seeking a diagnostic radiotracer for beta amyloid protein used in Alzheimer's patient PET imaging. Specifically, the solicitation is requesting SOFIE/Neuraceq-F-18 Florbetaben or an equivalent FDA-approved product. The contract will be a Firm-Fixed-Price, Indefinite Quantity agreement with a 12-month performance period. Suppliers must provide an Authorized Distributor Letter from the manufacturer dated within 90 days of submission and ensure compliance with all safety regulations for radioactive materials. Key technical requirements include providing bar-coded labels compatible with Nuclear Medicine Information System and delivering the product in liquid form. Potential vendors must submit their questions by January 30, 2025, at 4:00 PM PST, with final quotes due by February 3, 2025, at 4:00 PM PST.

The solicitation is not designated as a set-aside contract and will be awarded through the VA Network Contracting Office 22. The procurement is for 15 units of the diagnostic radiotracer, to be delivered to the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA. The contract falls under NAICS Category 339112 for Surgical and Medical Instrument Manufacturing and PSC Category 6515 for Medical and Surgical Instruments, Equipment, and Supplies. While specific award values are not explicitly stated, the requirement includes the radiotracer units plus associated handling costs. The place of performance is specifically designated as the VA medical facility in Los Angeles, indicating a localized procurement focused on supporting Alzheimer's diagnostic capabilities within the Veterans Health Administration's regional network.